Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model

Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model

Abstract Background Immunochemotherapy, the combined use of immunotherapy and chemotherapy, has demonstrated great promise in several cancers. LTX-315 is an oncolytic peptide with potent immunomodulatory properties designed for the local treatment of solid tumors. By inducing rapid immunogenic cell...

Full description

Bibliographic Details
Main Authors: Ketil A. Camilio, Meng-Yu Wang, Brynjar Mauseth, Stein Waagene, Gunnar Kvalheim, Øystein Rekdal, Baldur Sveinbjørnsson, Gunhild M. Mælandsmo
Format: Article
Language:English
Published: BMC 2019-01-01
Series:Breast Cancer Research
Subjects:
Triple-negative breast cancer
Immunochemotherapy
Combination therapy
Immunotherapy
Oncolytic peptide
LTX-315
Online Access:http://link.springer.com/article/10.1186/s13058-018-1092-x

Internet

http://link.springer.com/article/10.1186/s13058-018-1092-x

Similar Items